Your browser doesn't support javascript.
loading
The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue.
Beechinor, Ryan J; Mohyuddin, Ghulam Rehman; Mitchell, David E; Aaron, Daniel; Mahmoudjafari, Zahra.
Affiliation
  • Beechinor RJ; UC Davis Comprehensive Cancer Center, Sacramento, CA, USA; UCSF School of Pharmacy, San Francisco, CA, USA. Electronic address: rbeechinor@ucdavis.edu.
  • Mohyuddin GR; Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Mitchell DE; Cancer Patient, President and Founder, Patient for Affordable Drugs, 1120 20th Street NW, Washington, D.C., USA.
  • Aaron D; S.J. Quinney College of Law, University of Utah, Salt Lake City, USA.
  • Mahmoudjafari Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA; University of Kansas Medical Center, Westwood, KS, USA.
J Cancer Policy ; 38: 100446, 2023 12.
Article in En | MEDLINE | ID: mdl-37777010
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drugs, Generic / Medicare Part D Country/Region as subject: America do norte Language: En Journal: J Cancer Policy Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drugs, Generic / Medicare Part D Country/Region as subject: America do norte Language: En Journal: J Cancer Policy Year: 2023 Document type: Article Country of publication: